牛牛AI助理已提取核心訊息
Heart Test Laboratories, Inc. held its 2024 Annual Meeting of Shareholders on January 17, 2024, where shareholders voted on various proposals. However, Proposal 7, which sought to amend the Company's Certificate of Formation to decrease the number of shares required for a quorum at shareholder meetings, did not receive enough proxies to pass. Consequently, the meeting was adjourned, leveraging Proposal 8 which allows for adjournment to solicit additional proxies. The reconvened meeting is scheduled for February 15, 2024, and will be conducted via live audio webcast. Shareholders do not need to resubmit their proxies if they have already voted, and the votes will be counted at the reconvened meeting unless revoked. The record date for shareholder eligibility remains November 20, 2023. Heart Test Laboratories has hired Advantage Proxy...Show More
Heart Test Laboratories, Inc. held its 2024 Annual Meeting of Shareholders on January 17, 2024, where shareholders voted on various proposals. However, Proposal 7, which sought to amend the Company's Certificate of Formation to decrease the number of shares required for a quorum at shareholder meetings, did not receive enough proxies to pass. Consequently, the meeting was adjourned, leveraging Proposal 8 which allows for adjournment to solicit additional proxies. The reconvened meeting is scheduled for February 15, 2024, and will be conducted via live audio webcast. Shareholders do not need to resubmit their proxies if they have already voted, and the votes will be counted at the reconvened meeting unless revoked. The record date for shareholder eligibility remains November 20, 2023. Heart Test Laboratories has hired Advantage Proxy to aid in proxy solicitation for the reconvened meeting, with a base fee of $5,500 plus expenses. Approval of Proposal 7 requires a majority vote from the combined class of common stock and common stock issuable upon conversion of Series C Preferred Stock. Abstentions and broker non-votes will count as votes against the proposal, and without direct instructions from shareholders, brokers cannot vote on this non-routine item.
Heart Test Laboratories, Inc. 於2024年1月17日舉行了2024年年度股東大會，股東們對各種提案進行了投票。但是，旨在修改公司成立證書以減少股東大會法定人數所需的股份數量的提案7沒有獲得足夠的代理通過。因此，會議休會，利用第8號提案，該提案允許休會以徵集更多代理人。重新召開的會議定於2024年2月15日舉行，將通過網絡直播進行直播。如果股東已經投票，則無需重新提交代理人，除非被撤銷，否則選票將在重新召開的會議上進行計票。股東資格的記錄日期仍爲2023年11月20日。心臟測試實驗室已聘請Advantage Proxy協助爲續會的代理人招標，基本費用爲5,500美元，外加費用。第7號提案的批准需要C系列優先股轉換後可發行的普通股和普通股合併類別的多數票。棄權票和經紀人不投票將計爲反對該提案的票，如果沒有股東的直接指示，經紀人不能對這個非常規項目進行投票。
Heart Test Laboratories, Inc. 於2024年1月17日舉行了2024年年度股東大會，股東們對各種提案進行了投票。但是，旨在修改公司成立證書以減少股東大會法定人數所需的股份數量的提案7沒有獲得足夠的代理通過。因此，會議休會，利用第8號提案，該提案允許休會以徵集更多代理人。重新召開的會議定於2024年2月15日舉行，將通過網絡直播進行直播。如果股東已經投票，則無需重新提交代理人，除非被撤銷，否則選票將在重新召開的會議上進行計票。股東資格的記錄日期仍爲2023年11月20日。心臟測試實驗室已聘請Advantage Proxy協助爲續會的代理人招標，基本費用爲5,500美元，外加費用。第7號提案的批准需要C系列優先股轉換後可發行的普通股和普通股合併類別的多數票。棄權票和經紀人不投票將計爲反對該提案的票，如果沒有股東的直接指示，經紀人不能對這個非常規項目進行投票。
有用
沒用